États-Unis · Plateformes & données · Yahoo Finance

Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors

Publié par Yahoo Finance · États-Unis il y a 8 h

Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 inhibitors. The arrangement centers on small-molecule Sec61…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors

À lire aussi

Financial Institutions (FISI) Set to Release Quarterly Earnings on Thursday

IBM expects 2026 revenue growth of 4% to 5% while raising free cash flow growth view to more than $1B

Is This Cryptocurrency a Potential Millionaire-Maker?

My father-in-law, 81, sold his $75,000 home and paid off his daughter’s $50,000 debt. What happens to him now?

Nokia reports 9% Q3 sales growth, raises restructuring costs

SPCX Stock Eyes Best Week In Nearly 3 Months — But Analyst Warns Investors May Have To ‘Wait Decades’ To Justify Its Valuation

Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors

Partager

À lire aussi

Financial Institutions (FISI) Set to Release Quarterly Earnings on Thursday

IBM expects 2026 revenue growth of 4% to 5% while raising free cash flow growth view to more than $1B

Is This Cryptocurrency a Potential Millionaire-Maker?

My father-in-law, 81, sold his $75,000 home and paid off his daughter’s $50,000 debt. What happens to him now?

Nokia reports 9% Q3 sales growth, raises restructuring costs

SPCX Stock Eyes Best Week In Nearly 3 Months — But Analyst Warns Investors May Have To ‘Wait Decades’ To Justify Its Valuation